Investors largely expected the FOMC to cut rates by a quarter point.The Fedread more
India could benefit from the fallout in the U.S.-China trade war, experts told CNBC — but much-needed reforms on land and labor could prove to be a challenge for companies...Asia Economyread more
The FAA administrator's comments come on the eve of his visit to Boeing facilities outside Seattle. While there, he's scheduled to meet with Boeing executives and be briefed...Airlinesread more
As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
The photo depicts Canadian leader Justin Trudeau wearing a turban and robe, with dark makeup on his hands, face and neck. Liberal Party spokesman confirms the photo is of...Electionsread more
CBS, CNN and other major media companies are starting to pull e-cigarette advertising off their airways, as the death toll from a mysterious vaping-related illness continues...Health and Scienceread more
The U.S. Federal Reserve on Wednesday cut its overnight rate by 25 basis points to a range of 1.75% to 2%, a move that was widely expected. The central bank, however, appeared...Asia Marketsread more
Investors bought bank stocks because there's a chance the Federal Reserve's interest rate cut may "put an end to this artificially inverted yield curve," Jim Cramer says.Mad Money with Jim Cramerread more
AT&T is considering selling DirecTV, according to a report in the Wall Street Journal.Technologyread more
The Facebook CEO will talk to policymakers "about future internet regulation," according to a spokesperson.Technologyread more
Disney CEO Bob Iger writes in his autobiography that he believes he would have discussed combining Disney with Apple had Steve Jobs lived.Technologyread more
[The stream is slated to start at 4 p.m. ET. Please refresh the page if you do not see a player above at that time.]
The consumer products and pharmaceutical company, which makes everything from Tylenol to Aveeno lotions, was the only defendant in the seven-week trial in Cleveland County, which began May 28. Purdue Pharma, the privately held maker of OxyContin that has faced the brunt of the blame for the nationwide opioid epidemic, and Teva Pharmaceutical each reached a settlement with the Oklahoma attorney general's office before the trial began. Both companies did not admit to any wrongdoing.
Oklahoma Attorney General Mike Hunter claims J&J's sales practices created an oversupply of opioids and "a public nuisance" that upended lives and will cost the state $12.7 billion to $17.5 billion. The state is asking for more than $17 billion in damages.
J&J, which marketed the opioid painkillers Duragesic and Nucynta, has denied any wrongdoing.